FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

John Harlan

Research Profile

Chemicals & Drugs

Genes & Molecular Sequences

Amino Acid Sequences

Concepts & Ideas

Phenomena

Procedures

X Ray Crystallography

Occupations

Drug Design

Co-author Network

Publications

TOP 3
Charles A Flentge; John T Randolph; Peggy P Huang; Larry Klein; Kennan Marsh; John Harlan; Dale J Kempf
Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.
Liping Yu; Rohinton Edalji; John Harlan; Thomas F Holzman; Ana Pereda Lopez; Boris Labkovsky; Heinz Hillen; Stefan Barghorn; Ulrich Ebert; Paul L Richardson; Laura Miesbauer; Larry Solomon; Diane Bartley; Karl Walter; Robert W Johnson; Philip J Hajduk; Edward T Olejniczak
Structural characterization of a soluble amyloid beta-peptide oligomer.
F Luo; T R Seifert; Rohinton Edalji; R W Loebbert; Vincent P Hradil; John Harlan; M Schmidt; V Nimmrich; Bryan Cox; Gerard B Fox
Non-invasive characterization of beta-amyloid(1-40) vasoactivity by functional magnetic resonance imaging in mice.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of John Harlan (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2009: Charles A Flentge; John T Randolph; Peggy P Huang; Larry Klein; Kennan Marsh; John Harlan; Dale J Kempf
Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.
Bioorganic & medicinal chemistry letters 2009;19(18):5444-8.
2009: Liping Yu; Rohinton Edalji; John Harlan; Thomas F Holzman; Ana Pereda Lopez; Boris Labkovsky; Heinz Hillen; Stefan Barghorn; Ulrich Ebert; Paul L Richardson; Laura Miesbauer; Larry Solomon; Diane Bartley; Karl Walter; Robert W Johnson; Philip J Hajduk; Edward T Olejniczak
Structural characterization of a soluble amyloid beta-peptide oligomer.
Biochemistry 2009;48(9):1870-7.
2008: F Luo; T R Seifert; Rohinton Edalji; R W Loebbert; Vincent P Hradil; John Harlan; M Schmidt; V Nimmrich; Bryan Cox; Gerard B Fox
Non-invasive characterization of beta-amyloid(1-40) vasoactivity by functional magnetic resonance imaging in mice.
Neuroscience 2008;155(1):263-9.
2007: Zhihong Liu; Vincent S Stoll; Peter J Devries; Clarissa Jakob; Nancy Xie; Robert L Simmer; Susan E Lacy; David A Egan; John Harlan; Rick Lesniewski; Edward B Reilly
A potent erythropoietin-mimicking human antibody interacts through a novel binding site.
Blood 2007;110(7):2408-13.
2007: Claude G Lerner; Philip J Hajduk; Rolf Wagner; Frank L Wagenaar; Charlotte Woodall; Yu-Gui Gu; Xenia B Searle; Alan S Florjancic; Tianyuan Zhang; Richard F Clark; Curt S Cooper; Jamey C Mack; Liping Yu; Mengli Cai; Steven F Betz; Linda E Chovan; J Owen McCall; Candace L Black-Schaefer; Stephan J Kakavas; Mark Schurdak; Kenneth M Comess; Karl A Walter; Rohinton Edalji; Sarah A Dorwin; Richard A Smith; Eric J Hebert; John Harlan; Randy E Metzger; Philip J Merta; John L Baranowski; Michael L Coen; Susan J Thornewell; Annapur G Shivakumar; Anne Y Saiki; Niru Soni; Mai Bui; Darlene J Balli; William J Sanders; Angela M Nilius; Thomas F Holzman; Stephen W Fesik; Bruce A Beutel
From bacterial genomes to novel antibacterial agents: discovery, characterization, and antibacterial activity of compounds that bind to HI0065 (YjeE) from Haemophilus influenzae.
Chemical biology & drug design 2007;69(6):395-404.
2007: Karen Kage; Paul L Richardson; Linda M Traphagen; Jean M Severin; Ana Pereda-Lopez; Thomas Lubben; Rachel Davis-Taber; Melissa H Vos; Diane M Bartley; Karl Walter; John Harlan; Larry Solomon; Usha Warrior; Thomas F Holzman; Connie R Faltynek; Carol S Surowy; Victoria E Scott
A high throughput fluorescent assay for measuring the activity of fatty acid amide hydrolase.
Journal of neuroscience methods 2007;161(1):47-54.
2007: Kent D Stewart; Kevin Steffy; Kevin Harris; John Harlan; Vincent S Stoll; Jeffrey R Huth; Karl A Walter; Emily Gramling-Evans; Renaldo Mendoza; Jean M Severin; Paul L Richardson; Leo W Barrett; Edmund D Matayoshi; Kerry M Swift; Stephen F Betz; Steven W Muchmore; Dale J Kempf; Akhteruzzaman Molla
Design and characterization of an engineered gp41 protein from human immunodeficiency virus-1 as a tool for drug discovery.
Journal of computer-aided molecular design 2007;21(1-3):121-30.
2006: John Harlan; Y Chen; Earl J Gubbins; R Mueller; Jean M Roch; Karl Walter; Marc R Lake; T Olsen; P Metzger; Sarah A Dorwin; Uri S Ladror; David A Egan; Jean M Severin; Robert W Johnson; Thomas F Holzman; K Voelp; C Davenport; A Beck; J Potter; Murali Gopalakrishnan; A Hahn; Brian B Spear; Donald N Halbert; James P Sullivan; Victor Abkevich; Chris D Neff; Mark H Skolnick; Donna Shattuck; David A Katz
Variants in Apaf-1 segregating with major depression promote apoptosome function.
Molecular psychiatry 2006;11(1):76-85.
2005: Kenton Longenecker; Geoffrey F Stamper; Philip J Hajduk; Elizabeth H Fry; Clarissa Jakob; John Harlan; Rohinton Edalji; Diane M Bartley; Karl A Walter; Larry R Solomon; Thomas F Holzman; Yu Gui Gu; Claude G Lerner; Bruce A Beutel; Vincent S Stoll
Structure of MurF from Streptococcus pneumoniae co-crystallized with a small molecule inhibitor exhibits interdomain closure.
Protein science : a publication of the Protein Society 2005;14(12):3039-47.
2005: Wen-Zhen Gu; Ingrid B J K Joseph; Yi-Chun Wang; David Frost; Gerard M Sullivan; Le Wang; Nan-Horng Lin; Jerry Cohen; Vincent S Stoll; Clarissa Jakob; Steven W Muchmore; John Harlan; Thomas F Holzman; Karl A Walten; Uri S Ladror; Mark G Anderson; Paul Kroeger; Luis E Rodriguez; Ken Jarvis; Debra Ferguson; Kennan Marsh; Shichung Ng; Saul H Rosenberg; Hing L Sham; Haiying Zhang
A highly potent and selective farnesyltransferase inhibitor ABT-100 in preclinical studies.
Anti-cancer drugs 2005;16(10):1059-69.
2005: Stefan Barghorn; Volker Nimmrich; Andreas Striebinger; Carsten Krantz; Patrick Keller; Bodo Janson; Michael Bahr; Martin Schmidt; Robert S Bitner; John Harlan; Eve Barlow; Ulrich Ebert; Heinz Hillen
Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease.
Journal of neurochemistry 2005;95(3):834-47.
2005: Jianwei Shen; Tanveer Ahmed; Andrew Vogt; Jieyi Wang; Jean M Severin; Richard Smith; Sarah A Dorwin; Robert Johnson; John Harlan; Thomas F Holzman
Preparation and characterization of nitrilotriacetic-acid-terminated self-assembled monolayers on gold surfaces for matrix-assisted laser desorption ionization-time of flight-mass spectrometry analysis of proteins and peptides.
Analytical biochemistry 2005;345(2):258-69.
2005: Robert W Johnson; Tanveer F Ahmed; Laura J Miesbauer; Rohinton Edalji; Richard Smith; John Harlan; Sarah A Dorwin; Karl Walter; Thomas F Holzman
Protein fragmentation via liquid chromatography-quadrupole time-of-flight mass spectrometry: the use of limited sequence information in structural characterization.
Analytical biochemistry 2005;341(1):22-32.
2004: William J Sanders; Vicki L Nienaber; Claude G Lerner; J Owen McCall; Sean M Merrick; Susan J Swanson; John Harlan; Vincent S Stoll; Geoffrey F Stamper; Stephen F Betz; Kevin R Condroski; Robert P Meadows; Jean M Severin; Karl A Walter; Peter Magdalinos; Clarissa Jakob; Rolf Wagner; Bruce A Beutel
Discovery of potent inhibitors of dihydroneopterin aldolase using CrystaLEAD high-throughput X-ray crystallographic screening and structure-directed lead optimization.
Journal of medicinal chemistry 2004;47(7):1709-18.
2003: John Harlan; David A Egan; Uri S Ladror; Seth Snyder; M I Tang; Alex M Buko; Thomas F Holzman
Driving affinity selection by centrifugal force.
Assay and drug development technologies 2003;1(4):507-19.
2003: Björn Kauppi; Clarissa Jakob; Mathias Färnegårdh; Jie Yang; Harri Ahola; Maria Alarcon; Karin Calles; Owe Engström; John Harlan; Steven W Muchmore; Anna-Karin Ramqvist; Susanne Thorell; Lars Ohman; Jonathan Greer; Jan-�ke GUSTAFSSON; Jan Carlstedt-Duke; Mats Carlquist
The three-dimensional structures of antagonistic and agonistic forms of the glucocorticoid receptor ligand-binding domain: RU-486 induces a transconformation that leads to active antagonism.
The Journal of biological chemistry 2003;278(25):22748-54.
2000: J A Losonczi; Edward T Olejniczak; Stephen F Betz; John Harlan; Jamey Mack; Stephen W Fesik
NMR studies of the anti-apoptotic protein Bcl-xL in micelles.
Biochemistry 2000;39(36):11024-33.
1999: BS Chang; Ameeta Kelekar; Marian H Harris; John Harlan; Stephen W Fesik; Craig Thompson
The BH3 domain of Bcl-x(S) is required for inhibition of the antiapoptotic function of Bcl-x(L).
Molecular and cellular biology 1999;19(10):6673-81.
1998: X Liu; H Wang; M Eberstadt; A Schnuchel; Edward T Olejniczak; Robert P Meadows; Jeffrey M Schkeryantz; David A Janowick; John Harlan; Edith A S Harris; Donald E Staunton; Stephen W Fesik
NMR structure and mutagenesis of the N-terminal Dbl homology domain of the nucleotide exchange factor Trio.
Cell 1998;95(2):269-77.
1997: Ameeta Kelekar; BS Chang; John Harlan; Stephen W Fesik; Craig Thompson
Bad is a BH3 domain-containing protein that forms an inactivating dimer with Bcl-XL.
Molecular and cellular biology 1997;17(12):7040-6.
1997: Philip J Hajduk; Jurgen Dinges; G F Miknis; M Merlock; John Harlan; Dale J Kempf; David A Egan; Karl A Walter; T S Robins; Suzanne B Shuker; Thomas F Holzman; Stephen W Fesik
NMR-based discovery of lead inhibitors that block DNA binding of the human papillomavirus E2 protein.
Journal of medicinal chemistry 1997;40(20):3144-50.
1997: Kodi S Ravichandran; Ming-Ming Zhou; JC Pratt; John Harlan; Scott F Walk; S W Fesik; Steven J Burakoff
Evidence for a requirement for both phospholipid and phosphotyrosine binding via the Shc phosphotyrosine-binding domain in vivo.
Molecular and cellular biology 1997;17(9):5540-9.
1997: M Sattler; H Liang; David G Nettesheim; Robert P Meadows; John Harlan; M Eberstadt; H S Yoon; Suzanne B Shuker; B S Chang; A J Minn; Craig Thompson; Stephen W Fesik
Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis.
Science (New York, N.Y.) 1997;275(5302):983-6.
1996: Steven W Muchmore; M Sattler; H Liang; Robert P Meadows; John Harlan; H S Yoon; D Nettesheim; BS Chang; Craig Thompson; S L Wong; S L Ng; Stephen W Fesik
X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death.
Nature 1996;381(6580):335-41.
1995: M M Zhou; John Harlan; Warren Wade; S Crosby; Kodi S Ravichandran; Steven J Burakoff; Stephen W Fesik
Binding affinities of tyrosine-phosphorylated peptides to the COOH-terminal SH2 and NH2-terminal phosphotyrosine binding domains of Shc.
The Journal of biological chemistry 1995;270(52):31119-23.
1995: M M Zhou; Kodi S Ravichandran; E F Olejniczak; Andrew M Petros; Robert P Meadows; M Sattler; John Harlan; Warren Wade; Steven J Burakoff; Stephen W Fesik
Structure and ligand recognition of the phosphotyrosine binding domain of Shc.
Nature 1995;378(6557):584-92.
1995: John Harlan; H S Yoon; Philip J Hajduk; Stephen W Fesik
Structural characterization of the interaction between a pleckstrin homology domain and phosphatidylinositol 4,5-bisphosphate.
Biochemistry 1995;34(31):9859-64.
1995: John Harlan; D Picot; Patrick J Loll; R M Garavito
Calibration of size-exclusion chromatography: use of a double Gaussian distribution function to describe pore sizes.
Analytical biochemistry 1995;224(2):557-63.
1994: John Harlan; Philip J Hajduk; H S Yoon; Stephen W Fesik
Pleckstrin homology domains bind to phosphatidylinositol-4,5-bisphosphate.
Nature 1994;371(6493):168-70.
1982: G Graff; John Harlan; N Nahas
Preparation of phosphatidyl[2-3H]inositol from yeast grown in medium containing myo[2-3H]inositol.
Preparative biochemistry 1982;12(2):175-95.